Aligarh: In a ground-breaking achievement, the Interdisciplinary Brain Research Centre (IBRC), Faculty of Medicine, Aligarh Muslim University (AMU), has been granted an Indian patent for a novel compound named ARSH-Q. The compound is the result of rigorous research and extensive screening conducted by the Centre in collaboration with the Department of Applied Chemistry.
ARSH-Q has shown exceptional potential in inhibiting brain cancer cells by targeting stem cells, which are major contributors to resistance against radiation and chemotherapy. Given the high recurrence and mortality rates associated with brain cancer, this discovery brings significant hope for more effective treatment options.
Led by Dr. Mehdi Hayat Shahi, the research team, including Dr. Musheer Ahmad, Arif Ali, Mr. Mohd. Muzzammil, Ms. Basree, and Mr. Swalih P., developed ARSH-Q after screening numerous synthesised compounds. Dr. Shahi, whose research on brain tumours has been ongoing since 2005, focused extensively on the Sonic Hedgehog cell signalling pathway – a critical factor in stem cell-mediated brain cancer and other malignancies.
The team’s objective was to develop a compound that surpasses the efficacy of Temozolomide, the current standard chemotherapy drug. After extensive efforts, they successfully synthesised ARSH-Q, which has demonstrated exceptional results in suppressing brain cancer cells in initial studies.
Dr. Shahi and his team are now set to advance their research through pre-clinical studies to validate the efficacy of ARSH-Q. The goal is to develop the compound as either a standalone therapeutic agent or an adjuvant to existing chemotherapy treatments for brain cancer.
The team expressed gratitude to the Vice-Chancellor of AMU, the Dean of the Faculty of Medicine, the Convenor of the IPR Cell, and the Coordinator of IBRC for supporting the patent filing process and facilitating this significant research endeavour.
